Drug metabolism and clearance system in tumor cells of patients with multiple myeloma

作者：Hassen Wafa; Kassambara Alboukadel; Reme Thierry; Sahota Surinder; Seckinger Anja; Vincent Laure; Cartron Guillaume; Moreaux Jerome; Hose Dirk; Klein Bernard^*

来源：Oncotarget, 2015, 6(8): 6431-6447.

DOI：10.18632/oncotarget.3237

• Multiple Myeloma
• Drug Metabolism and Clearance
• Prognosis

Resistance to chemotherapy is a major limitation of cancer treatments with several molecular mechanisms involved, in particular altered local drug metabolism and detoxification process. The role of drug metabolism and clearance system has not been satisfactorily investigated in Multiple Myeloma (MM), a malignant plasma cell cancer for which a majority of patients escapes treatment. The expression of 350 genes encoding for uptake carriers, xenobiotic receptors, phase I and II Drug Metabolizing Enzymes (DMEs) and efflux transporters was interrogated in MM cells (MMCs) of newly-diagnosed patients in relation to their event free survival. MMCs of patients with a favourable outcome have an increased expression of genes coding for xenobiotic receptors (RXRa, LXR, CAR and FXR) and accordingly of their gene targets, influx transporters and phase I/II DMEs. On the contrary, MMCs of patients with unfavourable outcome displayed a global down regulation of genes coding for xenobiotic receptors and the downstream detoxification genes but had a high expression of genes coding for ARNT and Nrf2 pathways and ABC transporters. Altogether, these data suggests ARNT and Nrf2 pathways could be involved in MM primary resistance and that targeting RXRa, PXR, LXR and FXR through agonists could open new perspectives to alleviate or reverse MM drug resistance.

• 出版日期2015-3-20